June 2026

novo nordisk presented phase 2 diabetes data at ada — phase 3 for t2d is launching this half

On June 5, 2026, [Novo Nordisk announced Phase 2 results for zenagamtide](https://www.prnewswire.com/news-releases/novo-nordisks-investigational-zenagamtide-shows-significant-a1c-reductions-with-up-to-14-6-weight-loss-in-adults-with-type-2-diabetespresented-at-ada-2026--302793124.html) at the American Diabetes Association Scientific Sessions in New Orleans. The headline number: 14.6% weight loss at the highest dose tested, versus 2.1% for placebo, in 262 adults with type 2 diabetes not adequately controlled on metformin. Blood sugar control tracked alongside: A1C reductions reached -1.71% from baseline, with 89.1% of participants at the top dose reaching A1C below 7% at 36 weeks. The press release confirmed Novo Nordisk will advance zenagamtide to Phase 3 trials in adults with type 2 diabetes in the second half of 2026. September sits squarely in that window. The obesity Phase 3 program, called AMAZE, has been enrolling since February. Zenagamtide is the international nonproprietary name assigned to what early publications called amycretin. It is the same molecule.

The actual molecule

amycretin is the first unimolecular agonist of both glp-1 and amylin receptors — two satiety pathways from one drug

GLP-1 receptor agonism is not new. Semaglutide, tirzepatide, and nearly everything else in the obesity-drug pipeline hits the GLP-1 receptor as its primary lever — appetite suppression, slowed gastric emptying, glucose-dependent insulin release. What separates amycretin is the second receptor. Amylin is an endogenous peptide hormone co-secreted with insulin after meals, signaling satiety through pathways in the brainstem — particularly the area postrema and nucleus accumbens circuits — that are distinct from the hypothalamic routes where GLP-1 primarily acts. Pramlintide (Symlin), the approved amylin analog, has existed since 2005 and its satiety signal is documented in approved labeling for specific diabetes contexts. The design question amycretin is answering: what happens when both receptor-activation pathways run through a single engineered molecule rather than two separate drugs? That unimolecular framing describes a specific structural choice about how the two receptor affinities are built into one compound. [PubMed literature on amycretin](https://pubmed.ncbi.nlm.nih.gov/?term=Amycretin) covers the pharmacodynamic rationale from the earliest Phase 1 work forward.

The public narrative

the number circulating online is 13% at 12 weeks — and it needs context

The comparison in widest circulation comes from Novo Nordisk capital markets day data in 2024: the oral form of amycretin produced 13.1% mean weight loss at 12 weeks, versus 6% for oral semaglutide in what was presented as a comparable window. That data is real, and it is the reason amycretin advanced straight to Phase 3 without a traditional Phase 2 obesity trial. The inference online — that amycretin beats Ozempic — is also why context matters. This was not a head-to-head randomized study. It was a cross-trial comparison across separate populations, different baselines, and different measurement windows. The 24.3% weight loss figure for the subcutaneous formulation at 36 weeks, from [the Lancet-published Phase 1 obesity data](https://www.prnewswire.com/news-releases/novo-nordisk-advances-early-stage-obesity-medication-amycretin-to-phase-3-clinical-development-based-on-early-phase-clinical-trial-results-in-people-with-obesity-or-excess-weight-published-in-the-lancet-302487500.html), is a larger number — also real Phase 1 evidence. Phase 3 is what settles which number the drug actually defends at scale.

What the data says

three phase 2 readouts and a phase 3 that just started — the outcomes questions are still open

The evidence base for amycretin runs across three readouts. Subcutaneous Phase 1: 24.3% weight loss versus 1.1% placebo at 36 weeks, published in The Lancet in June 2025, which drove the Phase 3 decision. Oral Phase 1: 13.1% weight loss versus 1.2% placebo at 12 weeks, enabling parallel Phase 3 development for both formulations. T2D Phase 2, presented at ADA 2026: 14.6% weight loss, A1C reductions of up to -1.71% from baseline, 89.1% of participants reaching A1C below 7%, over 36 weeks in 262 patients with inadequately controlled diabetes. [ClinicalTrials.gov search for amycretin](https://clinicaltrials.gov/search?term=Amycretin) confirms the AMAZE Phase 3 program in active enrollment for obesity. The T2D Phase 3 is launching in H2 2026 — this half. What the evidence does not yet establish: long-term cardiovascular outcomes, lean mass preservation, GI tolerability at Phase 3 scale, and a direct-enrollment head-to-head comparison against tirzepatide or semaglutide. Those questions belong to the trials now running.

Early human — PeptideFactCheck stance

real phase 2 data, active phase 3 enrollment, and an approval clock that is still ticking

Amycretin holds the Early human evidence tier on PeptideFactCheck: interesting enough to watch, too early for broad certainty. Three Phase 2 readouts across two formulations and two indications, with numbers that cleared the bar for Phase 3 initiation — that is meaningful clinical evidence. What the tier captures is the gap between cleared Phase 2 and settled approval. The AMAZE obesity program is running; primary endpoints are years from completion. The T2D Phase 3 is launching now. Cardiovascular outcomes, the metric that drives long-term regulatory and commercial value in the metabolic drug class, belong to a later trial program not yet started. Amycretin is not available outside clinical trials, and no compounding pathway exists for it. [The FDA framework for the GLP-1 compound class](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) documents the regulatory landscape within which these investigational molecules operate. The combination of a new receptor-pairing mechanism, real Phase 2 data, and active Phase 3 enrollment makes amycretin the most mechanistically distinct investigational obesity drug in the Novo Nordisk pipeline right now. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.